Orchid Pharma growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+33.7%+22.8%
EBITDA−71.4%−26.2%
Net Income−90.0%−40.1%
EPS (adj.)−90.0%−40.1%
Total Assets+33.8%+22.6%
Total Equity+23.5%+31.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ORCHPHARMA₹865.00

Orchid Pharma Limited

· Pharma & Health
₹ CrorePeersFDCGUJTHEMIOLCPMOREPENLABRPGLIFEGUFICBIOINNOVACAPUNICHEMLABMcap ₹5,180 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+33.7+22.8
EBITDA-71.4-26.2
Net Income-90.0-40.1
EPS (adj.)-90.0-40.1
Total Assets+33.8+22.6
Total Equity+23.5+31.4
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.